Earnings ·
Kymera Therapeutics reported second quarter 2026 financial results, recognizing $65.0 million in collaboration revenue…
KYMRKymera Therapeutics, Inc.
Kymera Therapeutics reported second quarter 2026 financial results, recognizing $65.0 million in collaboration revenue driven by a $45 million option exercise fee from Gilead Sciences for KT-200 and a $20 million milestone payment from Sanofi for KT-485. The company posted a net loss of $61.2 million against R&D expenses of $119.5 million, while maintaining $1.5 billion in cash as of June 30, 2026. Clinically, enrollment in the Phase 2b BROADEN2 trial for KT-621 (STAT6) in atopic dermatitis completed nearly six months ahead of schedule, accelerating data readout to year-end 2026 and enabling a planned Phase 3 initiation by mid-2027. The company also appointed Felix J. Baker as Chairman and Terence Rooney as Chief Medical Officer. Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule therapies for immunological diseases.